vimarsana.com

Latest Breaking News On - Breakthrough therapy designations - Page 9 : vimarsana.com

Live from ASH 2023 | Results from Chinese Studies of Olverembatinib Presented in Oral Report at the ASH Annual Meeting for the Sixth Consecutive Year, Including Data Showing Promising Efficacy in Patients with TKI-Resistant and/or…

SUZHOU, China and ROCKVILLE, Md., Dec. 13, 2023 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a randomized, controlled, registrational Phase II study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in.

Qian jiangUnited statesSan diegoHong kongInnovent biologicsXiaojun huangAscentage pharmaYifan zhaiPrnewswire ascentage pharmaEastern cooperative oncology groupDana farber cancer instituteMd anderson cancer centerNational reimbursement drug listMajor nationalChina national medical products agencyUniversity people hospital

Live from ASH 2023 | Ascentage Pharma Presents the First Dataset of Bcl-2 inhibitor Lisaftoclax in Patients with AML, Demonstrating Favorable Efficacy and Safety

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesSan diegoHong kongHuafeng wangYifan zhaiPrnewswire ascentage pharmaAscentage pharmaJie jinNational reimbursement drug listDana farber cancer instituteFirst affiliated hospital of zhejiang universityAmerican society of hematologyChina national medical products administrationMajor nationalMd anderson cancer centerPoster presentation

Live from ASH 2023 | Ascentage Pharma Releases Encouraging Long-Term Data of Bcl-2 Inhibitor Lisaftoclax in R/R CLL, Including an ORR of 73 3%

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

Hong kongUnited statesSan diegoAscentage pharmaJianyong liPrnewswire ascentage pharmaKeshu zhouYifan zhaiAmerican society of hematologyMajor nationalMd anderson cancer centerChina national medical products administrationNational reimbursement drug listDana farber cancer institutePoster presentationAmerican society

Live from ASH 2023 | Ascentage Pharma Releases the First Dataset of Bcl-2 Inhibitor Lisaftoclax in Patients with R/R MM, Demonstrating Encouraging ORR and VGPR

/PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and.

United statesSan diegoHong kongYifan zhaiSikander ailawadhiPrnewswire ascentage pharmaAscentage pharmaDana farber cancer instituteNational reimbursement drug listChina national medical products administrationMd anderson cancer centerMajor nationalAmerican society of hematologyPoster presentationAmerican societyAnnual meeting

Live from ASH 2023 | Ascentage Pharma Presents Updated Data from US Study of Olverembatinib, Further Validating Encouraging Efficacy in Patients Resistant to Ponatinib or Asciminib

SUZHOU, China, and ROCKVILLE, Md., Dec. 10, 2023 /PRNewswire/ Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related diseases, announced today that it has released updated data from a US study of the company's novel drug candidate, olverembatinib (R&D code: HQP1351), in patients with refractory chronic.

San diegoUnited statesHong kongYifan zhaiAscentage pharmaElias jabbourDepartment of leukemiaMajor nationalAmerican society of hematologyChina national medical products administrationMd anderson cancer centerUniversity of texas md anderson cancer centerDana farber cancer instituteNational reimbursement drug listPoster presentationAmerican society

vimarsana © 2020. All Rights Reserved.